HOME >> BIOLOGY >> NEWS
Diabetes drug may be new tool in treating breast cancer

Washington, D.C Researchers at Georgetown University's Lombardi Comprehensive Cancer Center have decoded the step-by-step process by which a class of popular anti-diabetes drugs inhibits cancerous tumor growth. With the discovery of this molecular chain of events, as reported in the September 2003 issue of Molecular and Cellular Biology, the Georgetown researchers are now studying whether these anti-diabetes drugs, called glitazones, could one day be effective anti-cancer drugs.

Glitazones are taken by more than two million people with Type 2 diabetes. They are marketed under the names AvandiaTM and ActosTM, by SmithKline Beecham and Eli Lilly, respectively. Glitazones bind to a particular target on a cell, and in diabetics, they work by reducing insulin resistance at the sites of insulin action in the muscle and liver. Previous studies have also shown that glitazones also have the ability to inhibit tumor growth. However, until this study no one understood how this process worked.

"This study shows for the first time a direct link between a gene causing breast and other cancers and a gene linked to diabetes and the production of fat cells," said Richard Pestell, M.D., PhD, director of Lombardi Comprehensive Cancer Center. "The link between these cellular components may be a lynchpin in some cancers linking some cancers and metabolism directly. Potentially, we could be on the way to finding new therapeutic leads that would improve both diseases."

Pestell and his colleagues describe a complex relationship between a cancer causing gene, Cyclin D1, and a cancer-blocking receptor called PPAR gamma, which is involved in fat cell development. They are respectively found in breast cancer tissue and normal breast tissue. When PPAR is "turned on" by glitazones, tumor growth is inhibited. Conversely, when Cyclin D1 is activated in cells, it causes cancer cells to divide uncontrollably and excessively. <
'"/>

Contact: Elizabeth McDonald
eem6@georgetown.edu
202-687-5100
Georgetown University Medical Center
15-Sep-2003


Page: 1 2

Related biology news :

1. Joslin Diabetes Center honors brothers living 70-plus years with type 1 diabetes
2. Joslin Diabetes Center adds first affiliate in California at Irvine Medical Center
3. Joslin Diabetes Center launches research section on developmental and stem cell biology
4. Joslin Diabetes Center releases new low impact exercise video
5. As obesity skyrockets, Joslin Diabetes Center urges action to stem the tide of type 2 diabetes
6. Diabetes in the elderly linked to fewer cellular power plants
7. Diabetes therapies and liquid memory may develop from micro fluid research, Science researchers say
8. Diabetes tied to altering of the hearts circadian clock
9. Bacteria From Gum Infections Associated With Diabetes, Chronic Lung Disease, UB Studies Find
10. New Findings On Receptor Regulation May Lead To Better Drugs For Diabetes
11. Researchers Identify And Isolate First Gene For A Form Of Insulin-Dependent Diabetes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/22/2020)... Mass. (PRWEB) , ... April 21, 2020 , ... Worcester ... Africa to help provide critical medical supplies to address the expected spike of COVID-19 ... MS4SSA ) initiative, WPI has arranged for 3D printers and other materials to be ...
(Date:4/18/2020)... , ... April 17, 2020 ... ... miniature lab device that uses magnetic nano-beads to isolate minute bacterial particles ... strains of bacterial infections and difficult-to-detect micro-particles such as those making up ...
(Date:4/16/2020)... ... 2020 , ... RoosterBio Inc., a leading supplier of human ... the Medical Technology Enterprise Consortium (MTEC) recognized a multi-institution team with a “Prototype ... Regenerative Medicine (RegenMed) biomanufacturing collaboration had created a team initiative led by GenCure, ...
Breaking Biology News(10 mins):
(Date:4/22/2020)... ... 21, 2020 , ... Ripple Science today announced new initiatives ... are working remotely and have paused patient visits, forcing teams to do more ... during this uncertain time by giving research teams free access to Ripple for ...
(Date:4/7/2020)... ... 06, 2020 , ... Gateway Genomics , leading developer of direct-to-consumer genetic ... Gender DNA Tests sold in March, just months after attaining the 150,000-test landmark ... where a mom could order her kit online, collect a DNA sample from her ...
(Date:4/1/2020)... ... March 30, 2020 , ... Kinetic ... ArmourGuard® RTU, an EPA-approved spray-on antimicrobial solution. As a first-of-its-kind technology within the ... continual antimicrobial activity against microorganisms for up to 90 days. , In addition ...
(Date:4/1/2020)... ... March 31, 2020 , ... ... method using its revolutionary NEXTGENPCR endpoint thermocycler and consumables that decreases PCR ... increased samples per run, and standard, affordable laboratory equipment, a qualitative protocol ...
Breaking Biology Technology:
Cached News: